Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients

Cancer Investigation

Volumn 33, Issue 3, 2015, Pages 70-77

  Shameem, Raji ^a   Lacouture, Mario ^b   Wu, Shenhong ^c  

^a FOX CHASE CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

Cancer; Everolimus; mTOR inhibitor; mTOR inhibitor associated stomatitis (mIAS); Stomatitis; Temsirolimus

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; TEMSIROLIMUS; MTOR PROTEIN, HUMAN; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CANCER PATIENT; DRUG EFFECT; HIGH RISK POPULATION; HUMAN; INCIDENCE; META ANALYSIS; NEOPLASM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; STOMATITIS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; NEOPLASMS;

HUMANS; INCIDENCE; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SIROLIMUS; STOMATITIS; TOR SERINE-THREONINE KINASES;

EID: 84923206499     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2014.1001893     Document Type: Article

References (33)

1. Khokhar NZ, Altman JK, Platanias LC. Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies. Curr Opin Oncol 2011;23:578-586.
2. Gomez-Pinillos A, Ferrari AC. mTOR signaling pathway and mTOR inhibitors in cancer therapy. Hematol Oncol Clin North Am 2012;26:483-505.
3. Dabney R, Devine R, Sein N, George B. New agents in renal cell carcinoma. Target Oncol 2013, Nov 16 Target Oncol 2013;9(3):183-93.
4. Yuan R, Kay A, Berg WJ, Lebwohl D. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2009;2:45.
5. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005;16:525-537.
6. Ramirez-Fort MK, Case EC, Rosen AC et al. Rash to the mTOR Inhibitor Everolimus Systematic Review and Meta-Analysis. Am J Clinc Oncol 2012;37(3):266-71.
7. Sankhala K, Mita A, Kelly K et al. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target Oncol 2009;4:135-142
8. Ramalingam SS, Owanikoko TK, Behera M et al. Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer. J Thorac Oncol 2013;8:369-372.
9. Slomovitz BM, Lu KH, Johnston T et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 2010;116:5415-5419.
10. Oza AM, Elit L, Tsao MS et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol 2011;29: 3278-3285.
11. Okuno S, Bailey H, Mahoney MR et al. A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C). Cancer 2011;117:3468-3475.
12. Ansell SM, Inwards DJ, Rowland KM Jr et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008;113:508-514.
13. Renner C, Zinzani PL, Gressin R et al. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 2012;97:1085-1091.
14. Hess G, Herbrecht R, Romaguera J et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27:3822-3829.
15. Martins F, de Oliveira MA, Wang Q et al. A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol 2013;49:293-298.
16. Sonis S, Treister N, Chawla S et al. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 2010;116:210-215.
17. Boers-Doets CB, Raber-Durlacher J, Treister N et al. Mammalian target of rapamycin inhibitor-associated stomatitis. Future Oncol (London, England) 2013;9:1883-1892.
18. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials. Control Clin Trials 1996;17:1-12.
19. Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. New Engl J Med 2011;364:514-523.
20. Bissler JJ, Kingswood JC, Radzikowska E et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis placebo-controlled trial. Lancet 2013;381:817-824.
21. Ohtsu A, Ajani JA, Bai YX et al. Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study. J Clin Oncol 2013;31:3935-3943.
22. Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116:4256-4265.
23. Franz DN, Belousova E, Sparagana S et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex phase 3 trial. Lancet 2013;1:125-132.
24. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-529.
25. Bachelot T, Bourgier C, Cropet C et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012;30:2718-2724.
26. Baselga J, Semiglazov V, van Dam P et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27:2630-2637.
27. Pavel ME, Hainsworth JD, Baudin E et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011;378:2005-2012.
28. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-2281.
29. Wolff AC, Lazar AA, Bondarenko I et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as firstline endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2013;31:195-202.
30. de Oliveira MA, Martins F, Martins E et al. Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncol 2011;47:998-1003.
31. Gomez-Fernandez C, Garden BC, Wu S et al. The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis. Eur J Cancer 2012;48:340-346.
32. Carpenter JT, Roche H, Campone M et al. Randomized 3-arm, phase 2 study of temsirolimus (CCL-779) in combination with letrozole in post-menopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2005;23:19s (suppl 16; abstr 564).
33. Porta C, Osanto S, Ravoud A et al. Management of adverse effects associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2011;47:1287-1298.